Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations
This is more common during the dose-escalation phase when your body is still adapting to the medication
Sept 6: AstraZeneca will have to wait to add another indication to the label of blockbuster drug Ultomiris, as the FDA rejected the companys supplemental application in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease particularly affecting the optic nerve
Various components in our diet induce both pro-inflammatory and anti-inflammatory signals, influencing immune responses within the gut
Silva specializes in evidence-based weight management, including GLP-1 and GIP therapies such as semaglutide and tirzepatide
Her publications provide background for biochemistry-oriented discussion of melanocortin receptor families while keeping the page focused on research documentation, supplier review, and published literature boundaries